

ASSIGNMENT

For good and valuable consideration paid by **BRISTOL-MYERS SQUIBB COMPANY** with offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 US, (hereinafter referred to as "**ASSIGNEE**"), the receipt whereof is hereby acknowledged, effective as of February 3, 2023, **JANSSEN PHARMACEUTICA NV**, (hereinafter referred to as "**ASSIGNOR**"), a Belgian corporation with offices at Turnhoutseweg 30, Beerse, Belgium, 2340, does hereby assign to ASSIGNEE an undivided one-half (1/2) of the entire right, title and interest in all countries of the world to all of its invention and discoveries in "Milvexian Pharmaceutical Compositions", U.S. Patent Application Number 63/483,486, filed in the USPTO on February 6, 2023, including the right to claim priority, in and to all said inventions disclosed in and to said applications, and all foreign equivalents thereof, including all substitutions, divisions, and continuations thereof, and in and to all letters patents, that may be granted for said inventions, and in and to all extensions, renewals, and reissues thereof, the same to be held and enjoyed by said Assignee, its successors and assigns; and including any actions, claims and demands whatsoever, known or unknown, that ASSIGNOR may have had thereunder prior to the date of this Assignment, the same to be held and enjoyed by ASSIGNEE for its own use and benefit, and for its successors, assigns, and legal representatives, to the full end of the term for which said patent is or may hereafter be granted as fully and entirely as the same would have been held by ASSIGNOR had this assignment not been made.


This assignment includes the grant by the ASSIGNOR to the ASSIGNEE of the right to claim priority to the above-described patent applications under the International Convention for the Protection of Industrial Property and under any other international arrangement to which the United States of America is or hereafter becomes a signatory.

IN WITNESS WHEREOF, ASSIGNOR has caused this assignment to be executed on this 6th day of November, 2023.

JANSSEN PHARMACEUTICA NV

By: 
Name: Jan Van der Gotten
Title: Board Member

JANSSEN PHARMACEUTICA NV

By: 
Name: Tom Aelbrecht
Title: Board Member